Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3928/23258160-20231019-01 | DOI Listing |
Publication Analysis
Top Keywords
rwc update
4
update macular
4
macular indentation
4
indentation manage
4
manage complications
4
complications pathological
4
pathological myopia
4
myopia oct
4
oct biomarker
4
biomarker based
4
Similar Publications
RWC Update: Perforated Globe Secondary to Retrobulbar Anesthesia; Prophylactic Laser Photocoagulation vs Early Vitrectomy for the Management of Acute Retina Necrosis; Severe Anemia With Unilateral Swollen Nerve and White-Centered Retinal Hemorrhages.
Ophthalmic Surg Lasers Imaging Retina
January 2025
RWC Update: Uveal Effusion Syndrome; Peeling the Internal Limiting Membrane in Epiretinal Membrane Surgery; Partially Scrambled Best Disease.
Ophthalmic Surg Lasers Imaging Retina
December 2024
Article Synopsis
- JCO CheckMate 274 is a phase III trial comparing adjuvant nivolumab to placebo for high-risk muscle-invasive urothelial carcinoma (MIUC) post-surgery, showing improved disease-free survival (DFS) metrics with nivolumab treatment.
- The study documented results at a median follow-up of 36.1 months, with larger survival benefits noted for patients with positive PD-L1 expression.
- No new safety issues were discovered, reinforcing the role of nivolumab as standard treatment for high-risk MIUC following radical resection.
JCO Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of selected patients with papillary renal cell carcinoma (PRCC). In the phase II PAPMET trial (ClinicalTrials.gov identifier: NCT02761057), cabozantinib significantly prolonged progression-free survival and improved objective response rate compared with sunitinib in patients with advanced PRCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!